Loading
A phase 1/2 trial of Pembrolizumab, Olaparib, Docetaxel in prostate cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) is a phase 1/2 interventional study registered as NCT02861573 by Merck Sharp & Dohme LLC, with 1200 participants planned, started 2016-11-17 and due to reach its primary completion in 2027-10-22. Interventions recorded: Pembrolizumab 200 mg, Olaparib 400 mg, Docetaxel 75 mg/m^2, Prednisone 5 mg, Enzalutamide 160 mg. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Abiraterone acetate, Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer.
Shares Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD).
Shares Abiraterone acetate, Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer.
Shares Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD).
Shares Olaparib, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD).
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Olaparib, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors.